Zusammenfassung
Die Neuromyelitis optica (NMO; Devic-Syndrom) bezeichnet eine oft schwerwiegend verlaufende, idiopathische, entzündliche schubhaft-remittierende Erkrankung der Sehnerven sowie des Myelons. Die Abgrenzung der NMO von der Multiplen Sklerose (MS) als separate Entität wurde lange kontrovers diskutiert und ist klinisch insbesondere im Initialstadium der Erkrankung schwierig. Obwohl beide Erkrankungen mit Demyelinisierung einhergehen, unterscheiden sie sich in typischen klinischen, bildgebenden und immunpathologischen Befunden. Durch die Identifikation von Antikörpern gegen Aquaporin (AQP) im Serum bei Neuromyelitis optica ist es kürzlich gelungen, diese Erkrankung klar von der Multiplen Sklerose zu trennen. Darüber hinaus wird durch den Nachweis der Aquaporin-Antikörper die hämatogen-humorale Autoimmunpathogenese der NMO belegt und eine frühzeitige effektive Therapieeinleitung zur Verhinderung schubassoziierter Behinderung ermöglicht.
Abstract
Neuromyelitis optica (NMO; Devic's Syndrome) is an idiopathic, often relapsing, severe inflammatory disorder preferentially affecting optic nerves and spinal cord. The distinction of NMO from multiple sclerosis (MS) as a separate disease entity has been controversally discussed for a long time. Though both diseases show demyelinisation, they differ in typical clinical, imaging and immunopathological findings. The recent identification of serum aquaporin (AQP)-4 antibody clearly separates NMO from MS. In addition, the identification of AQP-4 antibodies supports peripheral humoral autoimmune pathogenesis in NMO and permits early initiation of effective therapy for prevention of attack-related disability.
Schlüsselwörter
Neuromyelitis optica - Aquaporin Antikörper - demyelinisierende Erkrankung - Optikusneuritis - Myelitis
Key words
Neuromyelitis optica - aquaporin antibody - demyelinating disorder - optic neuritis - myelitis
Literatur
-
1
Wingerchuk D M, Hogancamp W F, O'Brien P C, Weinshenker B G.
The clinical course of neuromyelitis optica (Devic's syndrome).
Neurology.
1999;
53
1107-1114
-
2
Lennon V A, Wingerchuk D M, Kryzer T J. et al .
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
Lancet.
2004;
364
2106-2112
-
3
Weinshenker B G.
Neuromyelitis optica is distinct from multiple sclerosis.
Arch Neurol.
2007;
64
899-901
-
4
Roemer S F, Parisi J E, Lennon V A. et al .
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.
Brain.
2007;
130
1194-1205
-
5
Wingerchuk D M, Lucchinetti C F.
Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis.
Curr Opin Neurol.
2007;
20
343-350
-
6
Wingerchuk D M, Lennon V A, Pittock S J, Lucchinetti C F, Weinshenker B G.
Revised diagnostic criteria for neuromyelitis optica.
Neurology.
2006;
66
1485-1489
-
7
Mandler R N.
Neuromyelitis optica - Devic's syndrome, update.
Autoimmun Rev.
2006;
5
537-543
-
8
Wingerchuk D M.
Neuromyelitis optica.
Int MS J.
2006;
13
42-50
-
9
Cree B A, Goodin D S, Hauser S L.
Neuromyelitis optica.
Semin Neurol.
2002;
22
105-122
-
10
Wingerchuk D M, Weinshenker B G.
Neuromyelitis optica: clinical predictors of a relapsing course and survival.
Neurology.
2003;
60
848-853
-
11
Wingerchuk D M, Pittock S J, Lucchinetti C F, Lennon V A, Weinshenker B G.
A secondary progressive clinical course is uncommon in neuromyelitis optica.
Neurology.
2007;
68
603-605
-
12
Jarius S, Franciotta D, Bergamaschi R. et al .
NMO-IgG in the diagnosis of neuromyelitis optica.
Neurology.
2007;
68
1076-1077
-
13
Pittock S J, Lennon V A, Krecke K, Wingerchuk D M, Lucchinetti C F, Weinshenker B G.
Brain abnormalities in neuromyelitis optica.
Arch Neurol.
2006;
63
390-396
-
14
Cabrera-Gomez J A, Quevedo-Sotolongo L, Gonzalez-Quevedo A. et al .
Brain magnetic resonance imaging findings in relapsing neuromyelitis optica.
Mult Scler.
2007;
13
186-192
-
15
Pittock S J, Weinshenker B G, Lucchinetti C F, Wingerchuk D M, Corboy J R, Lennon V A.
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression.
Arch Neurol.
2006;
63
964-968
-
16
Bergamaschi R, Tonietti S, Franciotta D. et al .
Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations.
Mult Scler.
2004;
10
2-4
-
17
Zaffaroni M.
Cerebrospinal fluid findings in Devic's neuromyelitis optica.
Neurol Sci.
2004;
25 Suppl 4
368-370
-
18
Nakamura M, Nakashima I, Sato S, Miyazawa I, Fujihara K, Itoyama Y.
Clinical and laboratory features of neuromyelitis optica with oligoclonal IgG bands.
Mult Scler.
2007;
13
332-335
-
19
Mandler R N, Dencoff J D, Midani F, Ford C C, Ahmed W, Rosenberg G A.
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic's neuromyelitis optica.
Brain.
2001;
124
493-498
-
20
Miyazawa I, Nakashima I, Petzold A, Fujihara K, Sato S, Itoyama Y.
High CSF neurofilament heavy chain levels in neuromyelitis optica.
Neurology.
2007;
68
865-867
-
21
Paul F, Jarius S, Aktas O. et al .
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica.
PLoS Med.
2007;
4
e133
-
22
Takahashi T, Fujihara K, Nakashima I. et al .
Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica.
Tohoku J Exp Med.
2006;
210
307-313
-
23
Takahashi T, Fujihara K, Nakashima I. et al .
Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.
Brain.
2007;
130
1235-1243
-
24
Weinshenker B G, Wingerchuk D M, Vukusic S. et al .
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.
Ann Neurol.
2006;
59
566-569
-
25
Lalive P H, Menge T, Barman I, Cree B A, Genain C P.
Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays.
Neurology.
2006;
67
176-177
-
26
Watanabe S, Nakashima I, Misu T. et al .
Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica.
Mult Scler.
2007;
13
128-132
-
27
Lennon V A, Kryzer T J, Pittock S J, Verkman A S, Hinson S R.
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.
J Exp Med.
2005;
202
473-477
-
28
Lucchinetti C F, Bruck W, Lassmann H.
Evidence for pathogenic heterogeneity in multiple sclerosis.
Ann Neurol.
2004;
56
308
-
29
de Seze J, Lebrun C, Stojkovic T, Ferriby D, Chatel M, Vermersch P.
Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis.
Mult Scler.
2003;
9
521-525
-
30 Sinclair C, Kirk J, Herron B, Fitzgerald U, McQuaid S. Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter. Acta Neuropathol (Berl) 2006
-
31
Misu T, Fujihara K, Kakita A. et al .
Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.
Brain.
2007;
130
1224-1234
-
32
Kister I, Gulati S, Boz C. et al .
Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy.
Arch Neurol.
2006;
63
851-856
-
33 Saiz A, Zuliani L, Blanco Y, Tavolato B, Giometto B, Graus F. Revised diagnostic criteria for neuromyelitis optica (NMO): Application in a series of suspected patients. J Neurol 2007
-
34
Jacob A, Matiello M, Wingerchuk D M, Lucchinetti C F, Pittock S J, Weinshenker B G.
Neuromyelitis optica: Changing concepts.
J Neuroimmunol.
2007;
187
126-138
-
35
Scott T F, Kassab S L, Pittock S J.
Neuromyelitis optica IgG status in acute partial transverse myelitis.
Arch Neurol.
2006;
63
1398-1400
-
36
Weinshenker B G, O'Brien P C, Petterson T M. et al .
A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.
Ann Neurol.
1999;
46
878-886
-
37
Wingerchuk D M, Weinshenker B G.
Neuromyelitis Optica.
Curr Treat Options Neurol.
2005;
7
173-182
-
38
Warabi Y, Matsumoto Y, Hayashi H.
Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination.
J Neurol Sci.
2007;
252
57-61
-
39
Papeix C, Vidal J S, de Seze J. et al .
Immunosuppressive therapy is more effective than interferon in neuromyelitis optica.
Mult Scler.
2007;
13
256-259
-
40
Mandler R N, Ahmed W, Dencoff J E.
Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine.
Neurology.
1998;
51
1219-1220
-
41
Bakker J, Metz L.
Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG).
Can J Neurol Sci.
2004;
31
265-267
-
42
Falcini F, Trapani S, Ricci L, Resti M, Simonini G, de Martino M.
Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment.
Rheumatology (Oxford).
2006;
45
913-915
-
43
Cree B A, Lamb S, Morgan K, Chen A, Waubant E, Genain C.
An open label study of the effects of rituximab in neuromyelitis optica.
Neurology.
2005;
64
1270-1272
-
44
Capobianco M, Malucchi S, di Sapio A. et al .
Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease).
Neurol Sci.
2007;
28
09-211
-
45
Freim Wahl S G, Folvik M R, Torp S H.
Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature.
Clin Neuropathol.
2007;
26
68-73
-
46
Weinstock-Guttman B, Ramanathan M, Lincoff N. et al .
Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).
Arch Neurol.
2006;
63
957-963
-
47
Weinshenker B G, Wingerchuk D M, Nakashima I, Fujihara K, Lennon V A.
OSMS is NMO, but not MS: proven clinically and pathologically.
Lancet Neurol.
2006;
5
110-111
-
48
Matsuoka T, Matsushita T, Kawano Y. et al .
Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese.
Brain.
2007;
130
1206-1223
-
49 Tanaka K, Tani T, Tanaka M. et al .Anti-aquaporin 4 antibody in selected Japanese multiple sclerosis patients with long spinal cord lesions. Mult Scler 2007
-
50
O'Riordan J I, Gallagher H L, Thompson A J. et al .
Clinical, CSF, and MRI findings in Devic's neuromyelitis optica.
J Neurol Neurosurg Psychiatry.
1996;
60
382-387
-
51
de Seze J, Stojkovic T, Ferriby D. et al .
Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile.
J Neurol Sci.
2002;
197
57-61
-
52
Reiber H, Ungefehr S, Jacobi C.
The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis.
Mult Scler.
1998;
4
111-117
-
53
Lucchinetti C F, Mandler R N, McGavern D. et al .
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.
Brain.
2002;
125
1450-1461
-
54
Ghezzi A, Bergamaschi R, Martinelli V. et al .
Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica.
J Neurol.
2004;
251
47-52
-
55
Reiber H.
Cerebrospinal fluid - physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases.
Mult Scler.
1998;
4
99-107
Dr. Berit Jordan
Klinik und Poliklinik für Neurologie, Martin-Luther-Universität Halle-Wittenberg
Ernst-Grube-Str. 40
06097 Halle/Saale
eMail: Berit.Jordan@medizin.uni-halle.de
